SummaryThis is a non-randomised, open-label trial with two parts evaluating Bempegaldesleukin (BEMPEG) in combination with nivolumab. In Part A, the trial is assessing the safety, tolerability and best dose level of the combined treatment. IN Part B, the trial is assessing the efficacy of the treatment amongst different cohorts based on tumour type. The cohorts include: Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Miscellaneous solid tumours, NHL/Leukaemia, High-grade Glioma, Medulloblastoma and Embryonal tumours, Ependymoma, and Miscellaneous brain tumours.
PIVOT IO 020
Use the hyperlinks, where available to access additional clinical trial information.
Bristol-Myers Squibb (BMS)
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)